(6R,7R)-7-[2-carboxy-2-(4-hydroxyphenyl)acetamido]-7-methoxy-3-{[(1-methyl-1H-1,2,3,4-tetrazol-5-yl)sulfanyl]methyl}-8-oxo-5-oxa-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid

• ChemBase编号: 4138
• 分子式: C20H20N6O9S
• 平均质量: 520.4726
• 单一同位素质量: 520.10124725
• SMILES: S(CC1=C(N2[C@H](OC1)[C@](OC)(NC(=O)C(c1ccc(O)cc1)C(=O)O)C2=O)C(=O)O)c1n(nnn1)C
• Canonical SMILES: CO[C@@]1(NC(=O)C(c2ccc(cc2)O)C(=O)O)C(=O)N2[C@@H]1OCC(=C2C(=O)O)CSc1nnnn1C
• InChI: InChI=1S/C20H20N6O9S/c1-25-19(22-23-24-25)36-8-10-7-35-18-20(34-2,17(33)26(18)13(10)16(31)32)21-14(28)12(15(29)30)9-3-5-11(27)6-4-9/h3-6,12,18,27H,7-8H2,1-2H3,(H,21,28)(H,29,30)(H,31,32)/t12?,18-,20+/m1/s1
• InChIKey: JWCSIUVGFCSJCK-CAVRMKNVSA-N

名称和登记号

名称

• IUPAC标准名: (6R,7R)-7-[2-carboxy-2-(4-hydroxyphenyl)acetamido]-7-methoxy-3-{[(1-methyl-1H-1,2,3,4-tetrazol-5-yl)sulfanyl]methyl}-8-oxo-5-oxa-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid
• IUPAC传统名: latamoxef
• 别名: 李斯特菌 MOX 添加剂; 拉氧头孢添加剂; Listeria MOX Supplement; Moxalactam Supplement; moxalactam; Latamoxef

登记号

• CAS号: 64952-97-2
• EC号: 265-287-9
• MDL号: MFCD00865991
• PubChem SID: 46505546; 160967570
• PubChem CID: 47499

理论计算性质

JChem

• Acid pKa: 2.920229
• 质子受体: 12
• 质子供体: 4
• LogD (pH = 5.5): -4.256628
• LogD (pH = 7.4): -6.684071
• Log P: 0.17177607
• 摩尔折射率: 133.7041 cm^3
• 极化性: 46.10878 Å^3
• 极化表面积: 206.3 Å^2
• 可自由旋转的化学键: 9
• 里宾斯基五规则: false

ALOGPS 2.1

• Log P: 0.22
• LOG S: -2.84
• 溶解度: 7.51e-01 g/l

分子性质

安全信息

• RTECS编号: RN6824500
• 德国WGK号: 3
• 个人保护装置: Eyeshields, Gloves, type N95 (US), type P1 (EN143) respirator filter
• 保存温度: 2-8°C

产品相关信息

• 级别: for microbiology
• 有效期: (limited shelf life, expiry date on the label)
• Empirical Formula (Hill Notation): C20H20N6O9S

详细说明

DrugBank - DB04570

• Drug Groups: approved
• Description: Broad- spectrum beta-lactam antibiotic similar in structure to the cephalosporins except for the substitution of an oxaazabicyclo moiety for the thiaazabicyclo moiety of certain cephalosporins. It has been proposed especially for the meningitides because it passes the blood-brain barrier and for anaerobic infections. [PubChem]
• Indication: Latamoxef is an oxacephem antibiotic usually grouped with the cephalosporins. It is used to treat bacterial infections. Latamoxef is primarily indicated in conditions like Bone and joint infection, GI infections, Gynecological infections, Meningitis, Respiratory tract infections, Septicaemia, Skin infections, Soft tissue infections, UTI.
• Pharmacology: Latamoxef works by inhibiting bacterial cell wall biosynthesis.
• Toxicity: Latamoxef produces potentially life-threatening effects which include Bleeding, Hypothrombinemia, Platelet dysfunctioning. which are responsible for the discontinuation of Latamoxef therapy.; The symptomatic adverse reactions produced by Latamoxef are more or less tolerable and if they become severe, they can be treated symptomatically, these include Diarrhea, Skin rashes, Hematuria, Hyperuricemia, Pyuria, Raised serum creatinine.
• Absorption: Rapidly absorbed after oral administration.
• Half Life: 1.6 hours
• Protein Binding: 40%
• Elimination: Renal Excretion accounts for 75 %
• Distribution: 8.51 L
• References: Weitekamp MR, Aber RC: Prolonged bleeding times and bleeding diathesis associated with moxalactam administration. JAMA. 1983 Jan 7;249(1):69-71. [Pubmed] ; Brown RB, Klar J, Lemeshow S, Teres D, Pastides H, Sands M: Enhanced bleeding with cefoxitin or moxalactam. Statistical analysis within a defined population of 1493 patients. Arch Intern Med. 1986 Nov;146(11):2159-64. [Pubmed]
• External Links: Wikipedia

Sigma Aldrich - 43963

Components
（每瓶，足够用于 1000mL 培养基） 拉氧头孢 20.0mg
General description
推荐用于选择性分离和培养单核细胞增多性李斯特菌的抗生素添加剂。

参考文献

• Weitekamp MR, Aber RC: Prolonged bleeding times and bleeding diathesis associated with moxalactam administration. JAMA. 1983 Jan 7;249(1):69-71. Pubmed
• Brown RB, Klar J, Lemeshow S, Teres D, Pastides H, Sands M: Enhanced bleeding with cefoxitin or moxalactam. Statistical analysis within a defined population of 1493 patients. Arch Intern Med. 1986 Nov;146(11):2159-64. Pubmed